DMPK Services

Pharmaron’s DMPK services support the needs for small molecule drug discovery, preclinical and clinical development, including preclinical candidate (PCC) identification and nomination, Investigational New Drug (IND) enabling and New Drug Application (NDA) packaging for regulatory submission. DMPK services are offered from our sites in China, United Kingdom and the United States.

Pharmaron’s DMPK group offers comprehensive in vitro ADME, radiolabelled metabolism, in vitro toxicity and in vivo pharmacokinetics services, which allow for the evaluation of DMPK properties and toxicity of small molecule drug candidates with high data quality in a cost-effective manner.

Our US Lab Services team provides express DMPK services that offer optimized, screening-based protocols with deliverables in 5-10 business days. For definitive studies to support regulatory approval, or to customize our online store assays, visit our E-Store.

in vitro ADME

  • Physical chemical properties
  • Drug absorption & transport
  • Drug metabolism
  • Drug-drug interactions

in vitro Toxicity

  • Liver toxicity package (general and mechanistic toxicity evaluation)
  • Phototoxicity (3T3 NRU)
  • Cardiotoxicity
  • Genotoxicity

in vivo PK

  • Formulation screening
  • Standard and special PK
  • Excretion balance
  • Tissue distribution
  • Metabolite quantification


  • Calibrated assays for better in vitro-in vivo correlation and human dose prediction
  • Comprehensive transporter platform; permeability/absorption models
  • Validated 3D models for evaluation of absorption and liver toxicity
  • in vitro liver toxicity platform to evaluate DILI risk at an early stage
  • Fully integrated automated ADME screening
lab chemistry beaker

Radiolabelled Metabolism

  • in vitro Metabolism using 14C- and 3H-labelled compounds
  • Tissue distribution and excretion using QWBA and mARG
Our Services


  • LC-MS/MS
  • Fully integrated automation
  • Liquid handlers
  • Multifunctional detectors
  • Radioactivity detectors